Cellular and molecular mechanisms underlying perturbed energy metabolism and neuronal degeneration in Alzheimer's and Parkinson's diseases

被引:288
作者
Mattson, MP [1 ]
Pedersen, WA [1 ]
Duan, WZ [1 ]
Culmsee, C [1 ]
Camandola, S [1 ]
机构
[1] NIA, Neurosci Lab, GRC 4F01, Baltimore, MD 21224 USA
来源
OXIDATIVE/ENERGY METABOLISM IN NEURODEGENERATIVE DISORDERS | 1999年 / 893卷
关键词
D O I
10.1111/j.1749-6632.1999.tb07824.x
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Synaptic degeneration and death of nerve cells are defining features of Alzheimer's disease (AD) and Parkinson's disease (PD), the two mast prevalent age-related neurodegenerative disorders. In AD, neurons in the hippocampus and basal forebrain (brain regions that subserve learning and memory functions) are selectively vulnerable. In PD dopamine-producing neurons in the substantia nigra-striatum (brain regions that control body movements) selectively degenerate. Studies of postmortem brain tissue from AD and PD patients hare provided evidence for increased levels of oxidative stress, mitochondrial dysfunction and impaired glucose uptake in,vulnerable neuronal populations. Studies of animal and cell culture models of AD and PD suggest that increased levels of oxidative stress (membrane Lipid peroxidation, in particular) may disrupt neuronal energy metabolism and ion homeostasis, by Impairing the function of membrane ion-motive ATPases and glucose and glutamate transporters. Such oxidative and metabolic compromise may thereby render neurons vulnerable to excitotoxicity and apoptosis. Studies of the pathogenic mechanisms of D-linked mutations in amyloid precursor protein (APP) and presenilins strongly support central roles for perturbed cellular calcium homeostasis and aberrant proteolytic processing of APP as pivotal events that lead to metabolic compromise in neurons. Specific molecular "players" in the neurodegenerative processes in AD and PD are being identified and include Par-4 and caspases (bad guys) and neurotrophic factors and stress proteins (good guys), Interestingly, while studies continue to elucidate cellular and molecular events occurring in the brain in AD and PD, recent data suggest that both AD and PD can manifest systemic alterations in energy metabolism (e.g., increased insulin resistance and dysregulation of glucose metabolism). Emerging evidence that dietary restriction can forestall the development of AD and PD is consistent with a major ''metabolic" component to these disorders, and provides optimism that these devastating brain disorders of aging may be largely preventable.
引用
收藏
页码:154 / 175
页数:22
相关论文
共 105 条
[1]   Protein oxidation and enzyme activity decline in old brown Norway rats are reduced by dietary restriction [J].
Aksenova, MV ;
Aksenov, MY ;
Carney, JM ;
Butterfield, DA .
MECHANISMS OF AGEING AND DEVELOPMENT, 1998, 100 (02) :157-168
[2]  
Alam ZI, 1997, J NEUROCHEM, V69, P1326
[3]   Oxidative DNA damage in the parkinsonian brain: An apparent selective increase in 8-hydroxyguanine levels in substantia nigra [J].
Alam, ZI ;
Jenner, A ;
Daniel, SE ;
Lees, AJ ;
Cairns, N ;
Marsden, CD ;
Jenner, P ;
Halliwell, B .
JOURNAL OF NEUROCHEMISTRY, 1997, 69 (03) :1196-1203
[4]   Synaptic plasticity in the caudate nucleus of patients with Parkinson's disease [J].
Anglade, P ;
MouattPrigent, A ;
Agid, Y ;
Hirsch, EC .
NEURODEGENERATION, 1996, 5 (02) :121-128
[5]   TUMOR-NECROSIS-FACTOR-ALPHA AND TUMOR-NECROSIS-FACTOR-BETA PROTECT NEURONS AGAINST AMYLOID BETA-PEPTIDE TOXICITY - EVIDENCE FOR INVOLVEMENT OF A KAPPA-B-BINDING FACTOR AND ATTENUATION OF PEROXIDE AND CA2+ ACCUMULATION [J].
BARGER, SW ;
HORSTER, D ;
FURUKAWA, K ;
GOODMAN, Y ;
KRIEGLSTEIN, J ;
MATTSON, MP .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (20) :9328-9332
[6]  
Barger SW, 1996, MOL BRAIN RES, V40, P116
[7]   Altered calcium homeostasis and mitochondrial dysfunction in cortical synaptic compartments of presenilin-1 mutant mice [J].
Begley, JG ;
Duan, WZ ;
Chan, S ;
Duff, K ;
Mattson, MP .
JOURNAL OF NEUROCHEMISTRY, 1999, 72 (03) :1030-1039
[8]  
Blanc EM, 1997, J NEUROCHEM, V68, P1870
[9]  
Blanc EM, 1998, GLIA, V22, P149, DOI 10.1002/(SICI)1098-1136(199802)22:2<149::AID-GLIA6>3.0.CO
[10]  
2-2